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KEY MESSAGE
Follow-up of children conceived through medically assisted reproduction (MAR) should be an integral part of 
introducing new reproductive technologies. This requires active involvement of families whose children were 
conceived through MAR and may hamper responsible follow-up research. Professionals may encourage such 
families to partake in follow-up research.
ABSTRACT
Research question: What ethical implications, issues and concerns play a role in conducting follow-up studies of 
children born after assisted reproductive technologies (ART)?
Design: Literature study and relevant experiences of academic medical centres in Brussels, Belgium, and Maastricht, 
the Netherlands were used to identify and analyse the most pertinent ethical implications, issues and concerns.
Results: According to recommendations from the European Society of Human Reproduction and Embryology, 
follow-up (ideally long term) of children conceived through medically assisted reproduction (MAR) should be an 
integral part of introducing new ART. With potentially risky new ART on the horizon, these recommendations need 
to be taken more seriously. Apart from practical barriers, such as funding, challenges for follow-up include securing 
active involvement of families of children conceived through MAR, starting with parents of young children, and ideally 
involving consenting adolescents and adults during a large part of their lives, possibly even into the next generation.
Conclusions: From an ethical viewpoint, the most pertinent issues include the proportionality of the inevitable 
burdens and risks for families of children conceived through MAR, and the implications of the principle of respect for 
autonomy. The proportionality requirement is most critical when it concerns incompetent children, who should not 
be included in research with more than minimal burdens and risks if there is no reasonable expectation of benefit for 
themselves. With respect for autonomy, we argue that, when seeking voluntary consent for participating in follow-
up studies that meet the condition of proportionality, professionals may encourage members of families of children 
conceived through MAR to partake in follow-up research.
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INTRODUCTION
M ore than 10 years ago, the European Society of Human Reproduction and Embryology (ESHRE) 
proposed an ideal research trajectory 
for evaluating the safety of new assisted 
reproductive technologies (ART), 
consisting of pre-clinical research, clinical 
studies and follow-up (Pennings et al., 
2007). With potentially risky new ART 
on the horizon, such as germline gene 
editing or the use of stem cell derived 
gametes, and with long-term safety data 
still being scarce even for existing ART, 
this approach is increasingly seen as 
essential to responsible innovation in the 
field of medically assisted reproduction 
(MAR) (Van Steirteghem, 2008; Harper 
et al., 2012; Provoost et al., 2014).
In this paper, we focus on the last step 
in ESHRE's recommended research 
trajectory: follow-up studies. Despite 
a consensus on the importance of 
follow-up, only a few centres conduct 
it. Practical and ethical concerns may 
hamper follow-up being carried out 
responsibly. Without the illusion of 
being exhaustive, we explore some of 
the most important ethical implications, 
issues and concerns relating to follow-up 
studies of children born after ART, taking 
into account the relevant experiences 
of academic medical centres in 
Brussels (Free University), Belgium, and 
Maastricht, the Netherlands.
In the next two sections we chart the 
envisioned benefits of MAR follow-up 
for its various stakeholders, describe 
the types of procedures involved and 
compare current practice against 
ESHRE's normative framework 
recommending follow-up as a part of 
responsible innovation in MAR. In the 
second part of the paper, we discuss 
proportionality and respect for autonomy 
as the two main ethical issues relevant for 
responsibly conducting follow-up.
BACKGROUND
Follow-up research in health care and 
medicine concerns the monitoring 
of health of patients over time after 
treatment. In the case of assisted 
reproduction, participants of such 
monitoring are not just patients (as for 
instance in the large number of studies 
that have been conducted to clarify 
whether hormonal stimulation puts 
women at a higher cancer risk later in 
their lives) but, importantly, also the 
resulting offspring. Follow-up of the latter 
is discussed in this paper.
Follow-up studies (both short- and 
long-term) of children conceived after 
assisted reproduction generate health-
impact data that may be important 
for four different groups of individual 
stakeholders, as well as for society 
at large. First, follow-up may benefit 
children born via the very procedures 
under evaluation. This is the case when 
health problems or health risks are found 
to be associated either with the use of 
a specific ART or its use in a specific 
population, and that allow for timely 
treatment or prevention. For example, 
the inheritance of infertility is not yet 
fully understood. Should an increased 
risk for premature menopause, for 
example, be found in girls conceived 
through MAR in a specific population, 
preventive actions might be taken, such 
as oocyte vitrification to expand their 
reproductive options. Follow-up studies 
revealing conditions or health risks that 
are ‘actionable’ in the sense of allowing 
for timely treatment or prevention can 
form the basis of professional guidelines 
for screening or monitoring the children 
to whom this may apply.
Second, long-term follow-up becomes 
transgenerational when the health of 
the descendants of children conceived 
through MAR are analysed. Any 
actionable findings entail that the 
benefits of follow-up extend to those 
in this further generation, most of 
whom will themselves be conceived 
without medical help. The importance 
of transgenerational follow-up is widely 
acknowledged in relation to deliberate 
interference of ART with the human 
germline (Watts et al., 2012; National 
Academies of Sciences, Engeneering and 
Medicine, 2016). It also seems important 
for ARTs more generally, given that 
possible epigenetic effects may affect 
next generations.
Third, findings that are used to make 
MAR procedures safer will benefit 
future children by reducing their 
chances of being born or having to 
live with ART-related malformations 
or disorders. Obviously, the parents 
and families of those children will also 
benefit from such adapted procedures. 
For example, research has shown that 
multiple pregnancies are associated 
with a higher rate of prematurity and 
low birth weight, which puts children at 
significant risk of adverse health effects 
(Lu et al., 2013). Therefore, ESHRE 
recommends single embryo transfer to 
avoid multiple pregnancies and advises 
not to transfer more than two embryos 
per cycle (De los Santos et al., 2016). 
Another example is the observation of a 
higher risk of malformations in children 
resulting from IVF involving oocytes 
with cytoplasmic smooth endoplasmic 
reticulum aggregates. In 2011, this 
finding led to the so-called Istanbul 
Consensus, which recommended that 
those oocytes should not be used in 
IVF (Alpha Scientists in Reproductive 
Medicine and ESHRE Special Interest 
Group of Embryology, 2011). In the light 
of conflicting evidence and the lack of a 
causal explanation, it was later advised 
to take a case by case approach (ESHRE 
Special Interest Group of Embryology 
and Alpha Scientists in Reproductive 
Medicine, 2017), with the authors of a 
recent review recommending a policy 
of giving embryos derived from oocytes 
with cytoplasmic smooth endoplasmic 
reticulum aggregates a lower priority 
ranking for transfer (Ferreux et al., 
2019). Although disregarding a small but 
significant percentage of oocytes that 
may still lead to healthy children has 
obvious implications for the success 
rate of IVF, the latter example is a good 
illustration of the complex trade-off 
that may exist between IVF safety and 
efficiency, and of the importance of 
conducting follow-up studies aimed 
at generating high-quality evidence 
required for sustainable policy decisions. 
Moreover, the example shows that 
epistemic uncertainty need not stand in 
the way of defining precautionary policy 
responses if more conclusive evidence is 
lacking (Jans et al., 2020).
Finally, follow-up contributes to 
informed decision making by couples 
or individuals undergoing MAR, as 
it enables a better understanding of 
the balance of benefits and risks of a 
certain reproductive technique. For 
example, follow-up of intracytoplasmic 
sperm injection for male infertility has 
shown that, compared with young men 
who were naturally conceived, those 
born after intracytoplasmic sperm 
injection had lower scores on sperm 
concentration, sperm count and sperm 
motility parameters (Belva et al., 2016). 
Such information is important when 
counselling couples who are considering 
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fertility treatment. To make an informed 
decision, they should be able to weigh up 
the pros and cons.
For society at large, it is important to 
consider that children conceived through 
MAR form an increasingly substantial 
part of the population, which means that 
even small MAR-related health risks can 
have a large effect on public health. For 
example, multiple studies have suggested 
that children conceived via MAR have an 
elevated risk of developing cardiovascular 
diseases later in life (van Ceelen et al., 
2008; Wikstrand et al., 2008; Scott 
et al., 2010; Scherrer et al., 2012). If 
adapted procedures, i.e. use of different 
culture media, can reduce those risks, 
this may have considerable population 
level benefits in addition to giving 
individuals conceived via ART healthier 
lives.
Follow-up of children conceived 
through MAR entails subjecting them 
to medical, psychological tests, or both, 
which may be invasive and are often 
recurrent. Medical tests can consist of 
assessment of possible (major or minor) 
malformations, measuring (birth) weight, 
growth, hearing, visual acuity, blood 
pressure and neurological examination, 
including testing movement, muscle 
tension, reflexes, large and fine motor 
skills and hand-eye coordination. These 
tests are carried out by a paediatrician 
or another healthcare professional. 
Also, reviewing the child's personal 
health record and, where relevant, the 
child's hospital records is usually part 
of follow-up. In long-term follow-up that 
aims to examine long-term treatment 
effects, medical tests may consist 
of analysing blood samples or saliva 
specimen and investigating reproductive 
health by analysing semen samples 
or examining female reproductive 
organs. Psychological tests may include 
analysing cognitive, motor and language 
developments, behaviour problems and 
socioemotional development, and the 
parent–child relationship (Zhan et al., 
2013; Heijligers et al., 2018). In practice, 
such tests include IQ tests, interviews 
and questionnaires.
To make information gained through 
follow-up available for studies 
evaluating long-term (transgenerational) 
consequences, it is recommended that 
centres facilitate a uniform data collection: 
a registry (Provoost et al., 2014). Such 
registries ‘could help document the risk 
of different ART for prospective children. 
Over time, this could provide the required 
evidence base that would allow regulators, 
professional societies and individual 
clinicians to better address the needs and 
concerns of prospective parents and to 
improve the risk communication process’ 
(Roy et al., 2017). Extensive registries are 
essential, because associations between 
aspects of a technique and certain health 
effects may only come to light much later. 
For example, documentation of specific 
embryo culture media is necessary to 
investigate possible associations between 
certain culture media and important 
offspring parameters, such as birth weight 
(Zandstra et al., 2015). Importantly, the 
value of such registries increases if a good 
registry of a control population exists.
FOLLOW-UP IN PRACTICE
To what extent is ESHRE's normative 
framework, specifically recommending 
follow-up studies, put into practice? 
Although follow-up is considered an 
important aspect of the responsible 
innovation of new reproductive 
treatments by commentators in the 
ART field, in practice few centres have 
experience in this regard (Brison et al., 
2013; Jans et al., 2020). Long-term follow 
up studies are rare (Mulder et al., 2018). 
Although some centres have contributed 
to follow-up studies extensively, such 
as at Brussels Free University Hospital, 
these centres are still the exception.
In many cases in which follow-up was 
conducted, studies had considerable 
methodological limitations (Sutcliffe and 
Ludwig, 2007; Mulder et al., 2018). One 
of the main limitations is the complexity 
of interpreting the scientific data, caused 
by using different IVF methods, lack 
of controls and differences in clinical 
definitions of outcome measures. 
Additionally, standard protocols on data 
collection are lacking, which hampers 
the collection of uniform data on health 
effects in children born after MAR 
(Mulder et al., 2018).
Practical difficulties are often cited 
as a reason behind the lack of 
(methodologically strong) follow-up 
research worldwide. Follow-up studies 
often lack funding, which may affect 
sample size or may complicate follow-
up being conducted at all. Long-term 
studies are costly, time consuming and 
often face high drop-out rates or loss to 
follow-up rates (Barnhart, 2013). In many 
countries, ‘basic’ scientific funding does 
not cover funding for follow-up research, 
and alternative funding is difficult to find. 
With some notable exceptions, such 
as Denmark (Norrman et al., 2020), 
governments often refrain from financially 
supporting fertility centres to carry out 
minimal follow-up. Participation rates are 
affected by logistical factors, such as the 
travel distance to the centre in which 
measurements are made, especially when 
families are expected to return every 
few years, and the time investment this 
entails for them. A further issue is that 
not all parents of children conceived 
via MAR tell their children about how 
they were conceived, which limits the 
willingness of families to participate 
in follow-up research, and also raises 
privacy issues complicating careful 
recruitment for such studies (Soini et al., 
2006).
Apart from possible privacy concerns 
relating to parental disclosure decisions, 
other ethical issues, i.e. the need for 
families of children conceived through 
MAR to lead normal lives, or the fact 
that children have not consented to be 
conceived through MAR, are sometimes 
raised as a ready and unchecked 
justification for not having to conduct 
adequate follow-up.
PROPORTIONALITY
As for all scientific research with human 
participants, the two main ethical issues 
relevant to assessing the acceptability 
of MAR follow-up are proportionality 
and respect for autonomy. We discuss 
these aspects in the following sections. 
The proportionality criterion generally 
requires that the possible benefits to 
be obtained from the relevant study 
clearly outweigh the possible risks and 
burdens for those asked to participate. 
Applying this to MAR follow-up, we 
first consider what possible risks and 
burdens participation in such research 
may entail. As a large part of MAR 
follow-up is research with children, we 
also need to discuss this in the context 
of internationally accepted guidance, as 
more stringent proportionality criteria 
apply for studies involving minors as 
research subjects.
Burdens and risks of participating 
in medically assisted reproduction 
follow-up studies
As follow-up of children, adolescents 
or adults born through MAR entails 
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subjecting them to medical and 
psychological tests, follow-up is inevitably 
associated with possible risks and 
burdens. These depend on the type of 
medical and psychological tests, their 
frequency and the overall duration 
of the follow-up study. Medical tests 
consisting of non-invasive check-ups, 
such as measuring weight or blood 
pressure, pose no risk and burden is 
minimal. Some tests, however, may be 
more invasive, e.g. blood drawing and 
tissue typing, especially when the latter 
requires a biopsy. Another example is the 
examination of the normal development 
of female reproductive organs, which 
requires a gynaecological examination. 
Naturally, in all cases, the preferred 
method for such examinations should 
be discussed with, and adapted to, the 
participants.
Follow-up may cause psychological 
burdens for the children and their 
families. To have one's reproductive 
organs investigated and to be asked 
questions relating to sexual development 
and behaviour may cause psychological 
discomfort. Moreover, follow-up 
consisting of frequent medical visits over 
a longer period may be psychologically 
exhausting. Families of children 
conceived through MAR may prefer to 
get on with their lives without repeated 
reminders of a history of infertility 
treatment. Additionally, children may 
face psychological burdens from feeling 
different from other children. Evidence 
that psychological burdens for children 
born after MAR are limited, and these 
studies did not specifically investigate 
psychological burdens caused by 
follow-up (Ponjaert-Kristoffersen et al., 
2004). In addition to the burdens and 
risks associated with testing procedures, 
a further possibly harmful effect of 
participating in MAR follow-up studies 
is the potential of findings revealing a 
serious health risk, leading to knowledge 
that may be experienced by the child 
and its parents, as casting a shadow over 
their lives. While this may be outweighed 
by the benefit of timely intervention 
in the case of actionable findings, e.g. 
when a girl is found to be at a high risk of 
developing hereditary breast or ovarian 
cancer, this is not the case for non-
actionable findings, e.g. a high risk of a 
neurodegenerative disorder for which no 
treatment or prevention options exist, 
i.e. Huntington's disease. Finally, the 
extent to which participating in follow-up 
is considered burdensome may differ 
between families and individuals, and 
highly specific practical aspects, such 
as travelling distance and related time 
investment, should be considered.
Medically assisted reproduction 
follow-up as research with minors
Follow-up of children born through 
MAR is mainly research with minors. 
Although MAR follow-up is ideally long 
term and will continue into adulthood, 
this typically extends a research trajectory 
that starts with including young children. 
Moreover, where long-term follow-
up becomes transgenerational, young 
children in the next generation will again 
become research subjects. According 
to internationally accepted guidance 
(Council of Europe, 1997; Doek et al., 
2009; CIOMS, 2017), minors may be 
included in research that has the potential 
to benefit themselves on the condition 
that risks are minimized and outweighed 
by the prospect of individual benefit. 
If there is no such potential, research 
with minors is only allowed if (apart from 
general research ethics requirements) 
both the following conditions are fulfilled: 
the research question can only be 
answered by conducting research with 
minors (criterion of group-relatedness); 
and the burdens and risks for those 
minors are minimal.
For our analysis, this guidance provides 
important context. Whereas it seems 
that MAR follow-up meets the criterion 
of group-relatedness (only research with 
children can give insight into the possible 
effect of being conceived through MAR 
on children's development), procedures 
involving more than minimal burdens 
and risks may only be considered when 
the child themselves can benefit. As 
indicated earlier, this may be the case 
when follow-up studies lead to findings 
revealing health problems or health 
risks that allow for timely treatment or 
prevention. An evidence-based likelihood 
of specific findings in this category 
would turn MAR follow-up into a form 
of ‘therapeutic research’ with minors. If 
such outcomes are a mere theoretical 
possibility, however, it would be difficult 
to take them as grounds for justifying 
procedures involving more than minimal 
burdens and risks.
Although more than minimal burdens 
and risks are acceptable in principle 
where non-therapeutic follow-up studies 
are conducted with competent adults 
able to provide informed consent (see 
below), adult offspring conceived through 
MAR are typically included in follow-
up only at a stage where the evidence 
base on the safety of the relevant ART is 
already quite robust. This means that the 
potential benefits for children, couples 
and public health to be expected from 
such studies will be smaller compared 
with those of follow-up in the initial 
stages of the development of a new ART. 
Moreover, as the ART through which 
they were conceived may over the years 
have undergone major adaptations, it will 
not always be obvious that the results 
of long-term follow up are still directly 
relevant for current practice. Therefore, 
although follow-up with adults allows 
giving more weight to third-party benefits 
when balancing these with the burdens 
and risks of follow-up, the case for doing 
so tends to weaken with the passing of 
time.
What we see here is a tension for which 
there is no easy solution: whereas the 
need for comprehensive safety data is 
greatest at the experimental stages of 
a potentially risky new technology, the 
scope for generating such data through 
follow-up studies in children is limited by 
the requirement of minimal burdens and 
risks.
RESPECT FOR AUTONOMY
If a follow-up study with either children 
or adults meets the proportionality 
requirement, the further criterion of 
respect for autonomy requires that 
families and individuals should only be 
recruited based on adequate informed 
consent. We summarize what this 
entails and discuss whether respect for 
autonomy allows centres or professionals 
to encourage families of children 
conceived through MAR to participate in 
follow-up.
Informed consent for medically 
assisted reproduction follow-up
As stated by Faden and Beauchamp 
(1986), for consent to be autonomous, it 
must be intentional, based on a proper 
understanding of what is at stake, and 
also voluntary, in the sense of being made 
without controlling external influences. 
As emphasized in this last condition, 
consent to participate in research should 
not just be informed, but decisions must 
be unconstrained and voluntary. Only 
then can such decisions be autonomous 
in the sense of being fully owned by 
those who make them.
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The age at which a young person 
can provide independent consent for 
participating in research ranges between 
16 and 18 years in different jurisdictions. 
Some countries, i.e. the Netherlands 
and Norway, maintain a dual consent 
procedure from the age of 12 years 
(with informed consent of both the 
child and their parents needed). Others 
require the child to be asked to ‘assent’ 
to the proposed research on the basis 
of information adapted to their level 
of understanding, again with different 
ages (often around 6–8 years) as from 
which this would be needed (European 
Medicines Agency, 2019). This notion 
of ‘assent’ (‘affirmative agreement’) has 
been criticized for being insufficiently 
clear, and also in its demarcation with 
the concept of consent (Baines, 2011). 
From an ethical viewpoint, it is important 
that children who are mature enough 
to make relevant decisions based on an 
adequate understanding of the nature of 
the research and its implications, can do 
so. Those who are not yet competent in 
this sense, should not be burdened with 
choices that are beyond their capacity 
for autonomous agency (Hein and 
Jõesaar, 2015). For them, the decision 
about participating in research should 
be made by their parents. Should a child 
who is not yet competent consistently 
resist being subjected to certain research 
procedures, such resistance should be 
respected unless participating is clearly 
in his or her own interest. As we have 
argued, this is hardly ever the case in the 
context of MAR follow-up.
Encouraging participation in medically 
assisted reproduction follow-up
According to a joint expert document 
from ESHRE and the European Society 
of Human Genetics ‘parents should be 
encouraged to take part in follow-up 
studies of health and development of 
their offspring’ (Soini et al., 2006). From 
the perspective of MAR professionals, 
this claim is understandable: they 
need the help of these families to be 
able to fulfill their own responsibility 
in the matter. But how does such 
encouragement relate to the requirement 
that participation should be based on 
voluntary consent, as stated above? 
Doesn't encouragement entail a form 
of mild moral pressure and, if so, would 
that be morally problematic? We suggest 
that this depends on whether families 
of children conceived through MAR 
(parents and children) can be said to 
have a certain responsibility to participate 
in follow-up. To the extent that they 
do, it can be argued that encouraging 
them may under certain conditions be 
acceptable. In the remainder of this 
section, we discuss two possible grounds 
for ascribing such a responsibility to 
the families of children conceived 
through MAR: parental responsibility and 
reciprocity.
Parental responsibility
At this point, a distinction must be made 
between a situation in which a potentially 
risky new ART is still experimental or 
innovative, and a situation in which it 
has become established treatment. In 
situations of the former kind, parents 
can be said to have a prima-facie 
responsibility towards their children to 
enrol them in follow-up research that 
may lead to findings revealing possible 
health problems or health risks that allow 
for timely treatment or prevention (Ishii, 
2019). The qualifier prima facie refers 
to the condition that the research in 
question must be proportional, also taking 
account of the burdens for the parents 
and their family. If so, reminding them, 
if necessary, of this responsibility is not 
at odds with respecting their autonomy, 
as long as their freedom to decide 
otherwise is respected. In cases in which 
an experimental new ART is introduced 
in the context of formal research aimed 
at generating initial data about safety and 
effectiveness, professionals may even go a 
step further and present a pre-treatment 
agreement to participate in follow-up 
as a condition of access (Watts et al., 
2012; Chen et al., 2016). Clearly this can 
only pertain to follow-up of incompetent 
minors rather than to long-term follow-
up for which the consent of the then 
adolescent or adult must be sought. 
Moreover, a pre-treatment parental 
agreement to this effect cannot be 
enforced, given that research participants 
or their legal representatives can always 
decide to retreat from a research project 
in which they participate (National 
Academies of Sciences, Engeneering and 
Medicine, 2016). Still, obtaining parents’ 
commitment to the implications of the 
experimental nature of the procedure is 
important in view of the need to reduce 
the uncertainties, as soon as possible, 
about offspring safety that may still exist 
at this early developmental stage of a 
potentially risky new ART (Watts et al., 
2012; Ishii, 2019).
As a further condition in this regard, 
couples undergoing experimental 
treatment in a formal research setting 
should be asked to commit themselves 
to telling their child how they were 
conceived. A survey-based study 
exploring the welfare of children born 
after experimental ooplasmic transfer 
conducted in the late 1990s showed that 
almost none of the respondent families 
had told their children about the mode 
of conception. The researchers surmise 
that precisely the use of an experimental 
procedure may have been an important 
factor in this decision (Chen et al., 2016).
Reciprocity
Clearly, the appeal to ‘parental 
responsibility’ loses most of its force 
when the new ART has become 
established treatment, meaning that data 
are sufficient to conclude that there are 
no serious concerns about its immediate 
safety (Provoost et al., 2014). There may, 
however, be a further moral reason for 
participation in MAR follow-up research, 
including active participation in long-
term follow up of those who themselves 
have been conceived through MAR. 
The general case for this argument has, 
somewhat provocatively, been presented 
by bioethicist John Harris (2005). He 
argues along two lines. Invoking the rule 
of rescue, he says that by volunteering 
as research subjects we can save others 
from serious harm and that if we can do 
so without excessive cost to ourselves, 
we have a duty to respond accordingly. 
Invoking the principle of fairness, his 
second argument is that, as members 
of modern western societies we all 
considerably benefit from advances in 
health care, and that, therefore, we have 
a prima-facie moral duty to reciprocate 
by contributing to medical research as 
the social practice that produces those 
very benefits. Failing to contribute while 
continuing to profit would amount to 
a form of morally reprehensible ‘free 
riding’ (Harris, 2005). According to 
Harris, the same reasoning extends to 
parents or other legal representatives 
deciding on behalf of children or 
incompetent adults. They may assume 
‘that the person they are making 
decisions for is, or would wish to be, a 
moral person who wants to or is in any 
event obliged to discharge his or her 
moral duties’(Harris, 2005, p 246).
Harris’ argument has met with criticism. 
Commentators have pointed out that 
his arguments fail to make the case for 
the supposed moral duty to participate 
in medical research (Brassington, 2007; 
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2011; Shapshay and Pimple, 2007). 
With the rule of rescue, the connection 
between participating in research and 
possibly saving human lives as a result is 
far too indirect to generate a similar call 
of moral duty as in the proverbial pond 
case where a child is drowning before 
one's eyes. Moreover, as a candidate 
research participant, one is hardly ever 
the only person around who might be 
able to respond. Also, while it may be 
true that fairness requires some form of 
reciprocation, it does not specify content 
and kind of what this should mean in 
practice. The most that can be argued 
is that all of us have an ‘imperfect moral 
duty’ to further the general good and 
that participating in scientific research is 
just one of many different ways in which 
we may choose to do so (Shapshay 
and Pimple, 2007). Still, the idea of 
participating in medical research as a 
possible way of fulfilling this imperfect 
duty means that deciding to do so is 
not entirely supererogatory in the sense 
of going beyond what morality might 
require us to consider. If so, it may well 
make a difference that our discussion is 
not about medical research in general 
but about follow-up research, in which 
only those can be asked to participate 
who have undergone the very procedure 
that is now being evaluated in the interest 
of future patients who may also need it. 
With regard to a possible contribution 
to medical research in general, a person 
need not have any specific reason for 
choosing this over other contributions 
that they might make to the general 
good, things may well be different when 
considering a request to participate in 
follow-up research. Here, the fact of 
being better placed than most others to 
make this specific contribution to the 
general good may amount to a moral 




Adequate follow-up research is an 
essential condition for introducing and 
innovating new reproductive techniques 
in a responsible way. Considering the 
clear benefits of follow-up for various 
stakeholders, the reproductive field 
should put more effort into actively 
implementing ESHRE's normative 
framework considering the execution of 
MAR follow-up. As the relevant studies 
inevitably involve burdens and risks, it 
is essential that its proportionality is 
assessed on a case-by-case basis. Where 
children who cannot yet themselves 
consent to participating are concerned, 
more than minimal burdens and risks are 
acceptable only where it is reasonable 
to expect that they themselves can 
benefit from taking part in the relevant 
studies. Follow-up research requires the 
active involvement of MAR families, with 
parents consenting for their children 
and adolescents asked to do so for 
themselves. When seeking their voluntary 
consent for participating in follow-up that 
meets the condition of proportionality, 
professionals may encourage MAR 
families to partake in follow-up research. 
The case for this is strongest where a 
potentially risky experimental ART is 
concerned, and such encouragement 
refers to a parental responsibility for 
the welfare of the child to be. Where 
such a new ART is introduced in the 
context of formal research, pre-treatment 
agreement to participation in follow-up 
may be presented as a (non-enforceable) 
condition for access. This also requires 
a parental commitment to tell their 
children how they were conceived. 
Where the relevant ART has become 
established treatment, there may still 
be grounds for encouraging parents of 
children conceived through and the 
children themselves to partake in follow-
up research based on the premise that 
they are better placed than others to 
make this specific contribution to the 
general good.
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